While shutting down an entity that assists individuals in assessing, predicting and remedying health issues, the wonderfully protective agency has rescinded restrictions on an anti diabetic drug fraught with cardiovascular adverse effects. My first thought was what committee member just received a speaking gig for the pharmaceutical industry, or has received new grant money?

http://www.medpagetoday.com/Endocrin...&mu_id=5531052

The FDA has loosened restrictions on the diabetes drug rosiglitazone (Avandia) -- under fire since 2007 because of potential cardiovascular risks -- and will allow drugmaker GlaxoSmithKline to drop the TIDE trial comparing rosiglitazone to pioglitazone (Actos), the only other thiazolidinedione available.